Current Status of Neuroendocrine Tumors with a Special Focus on Diagnosis and Novel Treatments

Dear Colleagues,

Neuroendocrine tumors are an increasing group of tumors. A majority are malignant, with local or distant metastases at diagnosis. Tumors are divided according to their proliferative rate into grade 1, grade 2, and grade 3 (G1, G2, and G3, respectively). Most tumors are G1 and G2, and hence slow-growing and patients suffering from such tumors may live for several years. Some tumors, however, are highly proliferative, and patients affected by them have a short survival and poor prognosis. Most G1 and G2 tumors, and some G3 tumors, express somatostatin receptors and may be detected by somatostatin receptor imaging. Diagnostic sensitivity has improved with the introduction of ⁶⁸Gallium-DOTATOC PET CT. Somatostatin analogues are the main treatment for patients with low proliferative tumors. Other treatments include chemotherapy, PRRT with ¹⁷⁷Lutetium-DOTATATE, and targeted therapies, such as Everolimus and Sunitinib, which have led to an improvement in prognosis. The need for newer therapeutic agents is, however, urgent.

This Special Issue will address the current knowledge at the epidemiologic, diagnostic, molecular, and therapeutic level, focusing on new diagnostic and therapeutic measures.

Dr. Dan Granberg
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.